Leap Therapeutics Stock Today
| LPTX Stock | USD 2.98 0.06 2.05% |
Performance3 of 100
| Odds Of DistressLess than 42
|
Leap Therapeutics is trading at 2.98 as of the 30th of November 2024; that is 2.05 percent increase since the beginning of the trading day. The stock's open price was 2.92. Leap Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Leap Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 2017 | Category Healthcare | Classification Health Care |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 38.32 M outstanding shares of which 1.42 M shares are now shorted by private and institutional investors with about 2.68 trading days to cover. More on Leap Therapeutics
Moving against Leap Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Leap Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLeap Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Leap Therapeutics' financial leverage. It provides some insight into what part of Leap Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Leap Therapeutics (LPTX) is traded on NASDAQ Exchange in USA. It is located in 47 Thorndike Street, Cambridge, MA, United States, 02141 and employs 54 people. Leap Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 111.89 M. Leap Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 38.32 M outstanding shares of which 1.42 M shares are now shorted by private and institutional investors with about 2.68 trading days to cover.
Leap Therapeutics currently holds about 90.88 M in cash with (43.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92.
Check Leap Therapeutics Probability Of Bankruptcy
Ownership AllocationLeap Therapeutics maintains a total of 38.32 Million outstanding shares. 30% of Leap Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Leap Ownership Details
Leap Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-06-30 | 172.1 K | |
| Ubs O'connor Llc | 2024-09-30 | 165.1 K | |
| Longwood Capital Partners Llc | 2024-09-30 | 120.5 K | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 113.7 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 81.5 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 79.8 K | |
| State Street Corp | 2024-06-30 | 71.8 K | |
| Northern Trust Corp | 2024-09-30 | 61.6 K | |
| Renaissance Technologies Corp | 2024-09-30 | 39.9 K | |
| Balyasny Asset Management Llc | 2024-09-30 | 3.1 M | |
| Samsara Biocapital, Llc | 2024-09-30 | 2.4 M |
Leap Therapeutics Historical Income Statement
Leap Stock Against Markets
Leap Therapeutics Corporate Management
| Augustine Lawlor | Chief Officer | Profile | |
| Cynthia MD | Chief Officer | Profile | |
| Christine Granfield | VP Quality | Profile | |
| Mark OMahony | Chief Officer | Profile | |
| Jason Baum | Chief Officer | Profile | |
| Cynthia Sirard | Chief Officer | Profile |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.